Evidence map›Paper›PMID 27217151›Full record

ArticleMolecular psychiatry2016

Mood, stress and longevity: convergence on ANK3.

S Rangaraju, D F Levey, K Nho, N Jain, K D Andrews, H Le-Niculescu, D R Salomon, A J Saykin, M Petrascheck, A B Niculescu

Open access · bronzeAbstract read
In one paragraph

Article in Molecular psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Lithium rescues dendritic abnormalities in Ank3 deficiency models through the synergic effects of GSK3β and cyclic AMP signaling pathways.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Increased Stress Resistance and Lifespan inMolecules (Basel, Switzerland) · 2021
    Article
  12. Review
  13. The aging transcriptome: read between the lines.Current opinion in neurobiology · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

S RangarajuDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
D F LeveyDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
K NhoIndiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.
N JainDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
K D AndrewsDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
H Le-NiculescuDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
D R SalomonDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
A J SaykinIndiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.
M PetrascheckDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
A B NiculescuDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Indiana University – Purdue University Indianapolis · USScripps Research Institute · USIndiana University School of Medicine

Funding

Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 1991 to 2020
$37.3M
Quantitative Biology CoreU19AI063603 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI YATES III, JOHN R · 2004 to 2015
$26.4M
Modulation of Sensory Perception to Treat Age Related DiseaseDP2OD008398 · OD · SCRIPPS RESEARCH INSTITUTE, THE · PI PETRASCHECK, MICHAEL · 2011 to 2011
$2.8M
Developing Blood Tests for Mood DisordersDP2OD007363 · OD · INDIANA UNIVERSITY INDIANAPOLIS · PI NICULESCU, ALEXANDER B · 2010 to 2010
$2.3M
Integration of Bio-, Medical, and Imaging Informatics for Complex DiseasesR00LM011384 · NLM · INDIANA UNIVERSITY INDIANAPOLIS · PI NHO, KWANGSIK TIMOTHY · 2013 to 2015
$647k
Integration of Bio-, Medical, and Imaging Informatics for Complex DiseasesK99LM011384 · NLM · INDIANA UNIVERSITY INDIANAPOLIS · PI NHO, KWANGSIK TIMOTHY · 2012 to 2012
$90k
Mood State Blood Biomarkers: A Discovery-Based ApproachI01CX000139 · VA · RLR VA MEDICAL CENTER · PI NICULESCU, ALEXANDER B · 2009 to 2017
–
CSRD VA I01 CX000139NIAID NIH HHS U19 AI063603NIA NIH HHS P30 AG010133NIH HHS DP2 OD007363NIH HHS DP2 OD008398NLM NIH HHS K99 LM011384NLM NIH HHS R00 LM011384
6 · The paper itself

Abstract

Antidepressants have been shown to improve longevity in C. elegans. It is plausible that orthologs of genes involved in mood regulation and stress response are involved in such an effect. We sought to understand the underlying biology. First, we analyzed the transcriptome from worms treated with the antidepressant mianserin, previously identified in a large-scale unbiased drug screen as promoting increased lifespan in worms. We identified the most robust treatment-related changes in gene expression, and identified the corresponding human orthologs. Our analysis uncovered a series of genes and biological pathways that may be at the interface between antidepressant effects and longevity, notably pathways involved in drug metabolism/degradation (nicotine and melatonin). Second, we examined which of these genes overlap with genes which may be involved in depressive symptoms in an aging non-psychiatric human population (n=3577), discovered using a genome-wide association study (GWAS) approach in a design with extremes of distribution of phenotype. Third, we used a convergent functional genomics (CFG) approach to prioritize these genes for relevance to mood disorders and stress. The top gene identified was ANK3. To validate our findings, we conducted genetic and gene-expression studies, in C. elegans and in humans. We studied C. elegans inactivating mutants for ANK3/unc-44, and show that they survive longer than wild-type, particularly in older worms, independently of mianserin treatment. We also show that some ANK3/unc-44 expression is necessary for the effects of mianserin on prolonging lifespan and survival in the face of oxidative stress, particularly in younger worms. Wild-type ANK3/unc-44 increases in expression with age in C. elegans, and is maintained at lower youthful levels by mianserin treatment. These lower levels may be optimal in terms of longevity, offering a favorable balance between sufficient oxidative stress resistance in younger worms and survival effects in older worms. Thus, ANK3/unc-44 may represent an example of antagonistic pleiotropy, in which low-expression level in young animals are beneficial, but the age-associated increase becomes detrimental. Inactivating mutations in ANK3/unc-44 reverse this effect and cause detrimental effects in young animals (sensitivity to oxidative stress) and beneficial effect in old animals (increased survival). In humans, we studied if the most significant single nucleotide polymorphism (SNP) for depressive symptoms in ANK3 from our GWAS has a relationship to lifespan, and show a trend towards longer lifespan in individuals with the risk allele for depressive symptoms in men (odds ratio (OR) 1.41, P=0.031) but not in women (OR 1.08, P=0.33). We also examined whether ANK3, by itself or in a panel with other top CFG-prioritized genes, acts as a blood gene-expression biomarker for biological age, in two independent cohorts, one of live psychiatric patients (n=737), and one of suicide completers from the coroner's office (n=45). We show significantly lower levels of ANK3 expression in chronologically younger individuals than in middle age individuals, with a diminution of that effect in suicide completers, who presumably have been exposed to more severe and acute negative mood and stress. Of note, ANK3 was previously reported to be overexpressed in fibroblasts from patients with Hutchinson-Gilford progeria syndrome, a form of accelerated aging. Taken together, these studies uncover ANK3 and other genes in our dataset as biological links between mood, stress and longevity/aging, that may be biomarkers as well as targets for preventive or therapeutic interventions. Drug repurposing bioinformatics analyses identified the relatively innocuous omega-3 fatty acid DHA (docosahexaenoic acid), piracetam, quercetin, vitamin D and resveratrol as potential longevity promoting compounds, along with a series of existing drugs, such as estrogen-like compounds, antidiabetics and sirolimus/rapamycin. Intriguingly, some of our top candidate genes for mood and stress-modulated longevity were changed in expression in opposite direction in previous studies in the Alzheimer disease. Additionally, a whole series of others were changed in expression in opposite direction in our previous studies on suicide, suggesting the possibility of a "life switch" actively controlled by mood and stress.

Indexed as

AgingAnimalsAnkyrinsBiomarkersCaenorhabditis elegansGene ExpressionGene Expression ProfilingGenome-Wide Association StudyHumansLongevityMianserinOxidative StressPolymorphism, Single NucleotideTranscriptomeANK3 protein, humanAnkyrinsBiomarkersMianserin

Identifiers

PMID27217151
PMCPMC9798616
OpenAlexW2406865086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.